FCRL1 immunoregulation in B cell development and malignancy

Immunotherapeutic targeting of surface regulatory proteins and pharmacologic inhibition of critical signaling pathways has dramatically shifted our approach to the care of individuals with B cell malignancies. This evolution in therapy reflects the central role of the B cell receptor (BCR) signaling...

Descripción completa

Detalles Bibliográficos
Autores principales: Mamidi, Murali K., Huang, Jifeng, Honjo, Kazuhito, Li, Ran, Tabengwa, Edlue M., Neeli, Indira, Randall, Nar’asha L., Ponnuchetty, Manasa V., Radic, Marko, Leu, Chuen-Miin, Davis, Randall S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10562807/
https://www.ncbi.nlm.nih.gov/pubmed/37822931
http://dx.doi.org/10.3389/fimmu.2023.1251127

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10562807/
https://www.ncbi.nlm.nih.gov/pubmed/37822931
http://dx.doi.org/10.3389/fimmu.2023.1251127

Ejemplares similares